Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

• Hoofdauteurs: Isabel Elías (Auteur), Itziar Oyagüez (Auteur), Luis Antonio Alvarez-Sala (Auteur), Fernando García-Bragadoa (Auteur), Andrés Navarro (Auteur), Paloma González (Auteur), Fernando de Andrés-Nogales (Auteur), Javier Soto (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2016-05-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Objective: Cost-effectiveness analysis of a 6-month treatment of apixaban (10 mg/12h, first 7 days; 5 mg/12h afterwards) for the treatment of the first event of venous thromboembolism (VTE) and prevention of recurrences, versus low-molecular-weight heparins/vitamin K antagonists treatment (LMWH/VKA)...